Adimolol (developmental code name MEN-935) is antihypertensive agent which acts as a non-selective α1-, α2-, and β-adrenergic receptor antagonist.[1]

Synthesis

The reaction between 1-naphthyl glycidyl ether (1) and 3-(3-amino-3-methylbutyl)-1H-benzimidazol-2-one (2) gives adimolol (3).[2][3]

Synthesis of adimolol

References

  1. ↑ Palluk R, Hoefke W, Gaida W, Mierau J, Bechtel WD (July 1986). "Interactions of MEN 935 (adimolol), a long acting beta- and alpha-adrenolytic antihypertensive agent, with postsynaptic alpha-adrenoceptors in different isolated blood vessels--influence of angiotensin II". Naunyn-Schmiedeberg's Archives of Pharmacology. 333 (3): 277–83. doi:10.1007/bf00512941. PMID 3020439. S2CID 24300936.
  2. ↑ Hoefke W, Gaida W, Palluk R, Mentrup A (1986). "Adimolol Hydrochloride Hydrate". Drugs of the Future. 11: 9. doi:10.1358/dof.1986.011.01.62036.
  3. ↑ US 4255430, Koppe H, Mentrup A, Renth EO, Schromm K, Hoefke W, Muacevic G, issued 1981, assigned to Boehringer Ingelheim Gmbh


source: https://en.wikipedia.org/wiki/Adimolol